Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.